hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Status:	Completed
Conditions:	Breast Cancer, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	11/21/2018
Start Date:	December 2014
End Date:	November 9, 2018

A Multi-center Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity
of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation
in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and
standard therapy. Subjects will be enrolled into one of ten treatment arms. Subjects will be
assessed according to standard of care. Restaging and imaging studies will be performed to
assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in
cases of relapse.

Inclusion Criteria:

- 1. Signed and dated written IRB approved informed consent;

- 2. Males or females aged ≥18 years;

- 3. Subjects with breast, lung or pancreatic carcinoma who are at high risk of relapse
post definitive therapy at least 4 and no more than 24 weeks from completion of
definitive therapy at the time of signing informed consent as described below for each
indication:

- Breast carcinoma:

- Lung carcinoma:

- Pancreatic carcinoma:

- Head and neck squamous cell carcinoma:

- Ovarian cancer:

- Colorectal cancer

- Gastric and esophageal cancer

- Hepatocellular carcinoma

Exclusion Criteria:

- 1. Previous treatment wth any TERT or IL-12 containing therapy, or any other DNA
immunotherapy;

- 2. Any concurrent condition requiring the continued or anticipated use of systemic
steroids (excluding non-systemic inhaled, topical skin and/or eye drop-containing
corticosteroids) or immunosuppressive therapy (excludes low dose methotrexate). All
other systemic corticosteroids must be discontinued at least 4 weeks prior to first
Study Treatment;

- 3. Administration of any vaccine within 4 weeks of the first study treatment

We found this trial at

sites

University of Pittsburgh

4200 Fifth Ave
Pittsburgh, Pennsylvania 15260

(412) 624-4141